Related Experiment Video
Updated: May 26, 2026

Generation of Multivirus-specific T Cells to Prevent/treat Viral Infections after Allogeneic Hematopoietic Stem Cell Transplant
Published on: May 27, 2011
Management of multidrug-resistant viruses in the immunocompromised host
1Department of Haematology, University College London Cancer Institute, 72 Huntley Street, London WC1E 6DD, UK. k.peggs@cancer.ucl.ac.uk
Abstract:
Multidrug-resistant viruses remain a clinically challenging complication in the immunocompromised host. This review discusses mechanisms of viral resistance and treatment options in this context with particular emphasis on the immunocompromised haematology patient. We also outline some of the newer agents and treatment strategies being developed to treat multidrug-resistant viruses.
Related Concept Videos
Retrovirus Life Cycles
Pneumonia IV: Management
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Pulmonary Tuberculosis I
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Inhibitors of Viral Protein Synthesis
Pulmonary Tuberculosis V
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the progression...
Pharmacokinetics in Pediatric Patients: Drug Excretion

